Zobrazeno 31 - 40
of 44
pro vyhledávání: '"Marina Y. Konopleva"'
Autor:
Ahmad S, Alotaibi, Mustafa, Abdulrazzaq, Keyur P, Patel, Farhad, Ravandi, Sergej, Konoplev, Carlos, Bueso-Ramos, C Cameron, Yin, Tariq, Muzzafar, Guilin, Tang, Andrew, Futreal, Nitin, Jain, Marina Y, Konopleva, Naveen, Pemmaraju
Publikováno v:
Leukemialymphoma. 61(12)
Autor:
Lina Han, Antonio Cavazos, Natalia Baran, Qi Zhang, Vinitha Mary Kuruvilla, Jason P Gay, Ningping Feng, Venkata Lokesh Battula, Hagop M. Kantarjian, Naval G. Daver, Joseph R Marszalek, Michael Andreeff, Marina Y Konopleva
Publikováno v:
Blood. 134:5161-5161
Acute myeloid leukemia (AML) is initiated and maintained by a relatively rare leukemia stem cells (LSCs) capable of self-renewal and proliferation. Recent data showed that LSCs (Lagadinou et al. Cell Stem Cell 2013) and residual cytarabine (Ara-C)-re
Autor:
Jorge M. Ramos Perez, Tapan M. Kadia, Guillermo Montalban-Bravo, Christopher B. Benton, Stefan Faderl, Koji Sasaki, Kiran Naqvi, Jorge E. Cortes, Naval G. Daver, Courtney D. DiNardo, Elias Jabbour, Gautam M. Borthakur, Hind Al Azzawi, Naveen Pemmaraju, Marina Y Konopleva, Sherry A. Pierce, Nitin Jain, Maro Ohanian, Guillermo Garcia-Manero, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi, Yesid Alvarado
Publikováno v:
Blood. 134:2642-2642
INTRODUCTION: The outcome of patients (pts) with relapsed or refractory AML (R/R AML) or MDS after failing hypomethylating agents (HMA) is poor. CPX-351 is a liposomal formulation of cytarabine and daunorubicin, approved by the US Food and Drug Admin
Autor:
Koichi Takahashi, P Andrew Futreal, Guillermo Garcia-Manero, Richard E. Champlin, Hagop M. Kantarjian, Marina Y Konopleva, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Jairo Matthews, Curtis Gumbs, Latasha Little, Feng Wang, Kiyomi Morita, Tomoyuki Tanaka
Publikováno v:
Blood. 134:17-17
Introduction While clonal hematopoiesis (CH) can precede the development of AML, preleukemic CH can persist after attaining remission. In rare cases, non-leukemic CH can also emerge after remission. Long-term clonal dynamics of persistent CH or emerg
Autor:
Naval G. Daver, Harry P. Erba, Nikolaos Papadantonakis, Daniel J. DeAngelo, Eunice S. Wang, Marina Y Konopleva, Callum M. Sloss, Jiuzhou Wang, Kara E. Malcolm, Patrick A. Zweidler-McKay, Hagop M. Kantarjian
Publikováno v:
Blood. 134:2601-2601
Background: Overexpression of CD123, the alpha subunit of the IL-3 receptor, is characteristic of a number of hematological malignancies, including acute myeloid leukemia (AML), thus providing an attractive candidate for targeted therapeutic approach
Autor:
Courtney D. DiNardo, Marina Y Konopleva, Hagop M. Kantarjian, John S. Welch, Wei Qiao, Jing Ning, Sherry A. Pierce, Kenneth Vaughan, Robin Thomas, Susan Tse, Shadiat L Adewale, Allison Wade, Carol A. Bivins, Helen Ma, Antonio Cavazos, Qi Zhang, Julio A Guerrero, Rita Maduike, Maitrayee Goswami, Zhining Chen, Sergej Konoplev, Sa A Wang, Philip A. Thompson, Michael E. Rytting, Lucia Masarova, Elias Jabbour, Ghayas C. Issa, Alessandra Ferrajoli, Prithviraj Bose, Michael Andreeff, Koji Sasaki, Guillermo Montalban Bravo, Steven M. Kornblau, Nitin Jain, Musa E. Yilmaz, Koichi Takahashi, Tapan M. Kadia, Christopher B. Benton, Yesid Alvarado, Nicholas J. Short, Maro Ohanian, Kiran Naqvi, Gautam M. Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Naval G. Daver, Naveen Pemmaraju, Jorge E. Cortes, Caitlin R. Rausch, Abhishek Maiti
Publikováno v:
Blood. 134:738-738
Background: Acute myeloid leukemia (AML) outcomes in the elderly, particularly intensive chemotherapy (IC)-ineligible patients (pts), are poor. Venetoclax (VEN), a BCL2 inhibitor, in combination with low-intensity regimens has shown excellent efficac
Autor:
Pandey Renu, Marina Y Konopleva, Stefano Tiziani, Joseph R Marszalek, Philip Lorenzi, Maria E Di Francesco, Adolfo A. Ferrando, Elias Jabbour, Sergej Konoplev, Marcin Kaminski, Jason P Gay, Ningping Feng, Karine Harutyunyan, Eric Davis, Marc Warmoes, Anna Skwarska, Daniel Herranz, Antonio Cavazos, Vinitha Mary Kuruvilla, Shannon Renee Sweeney, Alessia Lodi, Natalia Baran
Publikováno v:
Blood. 134:806-806
Notch1-mutated T-ALL is an aggressive hematologic malignancy lacking targeted therapeutic options. Genomic alterations in Notch1-gene and its activated downstream pathways are associated with metabolic stress response and heightened glutamine (Gln) u
Autor:
Mansour Alfayez, Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Marina Y. Konopleva, Naval G. Daver, Courtney D. DiNardo, Gautam Borthakur, Prithviraj Bose, Michael Andreeff, Yesid Alvarado, Musa E. Yilmaz, Naveen Pemmaraju, Steven M. Kornblau, Zeev E. Estrov, Christopher B. Benton, Koichi Takahashi, Kiran Naqvi, Rebecca Slack, Rubiul Islam, Elias J. Jabbour, Jorge E. Cortes, Tapan M. Kadia
Publikováno v:
Blood. 132:4039-4039
Background Nucleoside analogues such as cladribine can increase the efficacy of cytarabine (araC) by modulating deoxycytidine kinase. The addition of cladribine to standard 7+3 chemotherapy has been shown to improve survival in pts with AML (Holowiec
Autor:
Naval G. Daver, Rita Assi, Hagop M. Kantarjian, Jorge E. Cortes, Farhad Ravandi, Marina Y. Konopleva, Tapan M. Kadia, Gautam Borthakur, Elias J. Jabbour, Courtney D. DiNardo, Michelle Velasquez, Mary Kelly, Jing Ning, Graciela M. Nogueras González, Sherry A. Pierce, Dan Gombos, Zeev E. Estrov, Steven M. Kornblau, Weiguo Zhang, Michael Andreeff
Publikováno v:
Blood. 132:1441-1441
Responses to FLT3-inhibitors are usually transient due to emergence of resistance through the acquisition of kinase domain point mutations and other non-mutational mechanisms. SEL is a potent first-in-class Selective Inhibitor of Nuclear Export/SINE
Autor:
Catherine Kendall Major, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Naveen Pemmaraju, Nicholas J Short, Naval G. Daver, Elias J. Jabbour, Richard E Champlin, Guillermo Garcia-Manero, Marina Y. Konopleva, Michael Andreeff, Steven M. Kornblau, William G. Wierda, Sherry A. Pierce, Farhad Ravandi, Jorge E. Cortes
Publikováno v:
Blood. 132:3976-3976
Introduction: Approximately 77% of younger pts and 49% of older pts with newly diagnosed AML achieve CR after induction chemotherapy (chemo). The majority of pts who achieve CR eventually relapse, with only approximately 30% of pts maintaining CR for